Renalytix AI (RNLX) has released an update to notify the public and investors about a regulation fd disclosure.
Renalytix plc announced that the Centers for Medicare & Medicaid Services (CMS) has released a draft local coverage determination for KidneyIntelX and KidneyIntelX.dkd, marking a significant milestone for the company. This development could impact the stock as it reflects the company’s progress in gaining insurance coverage for its kidney function tests, although the information has not been filed for legal purposes nor is it influencing any current registration statements or documents under securities law.
For further insights into RNLX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
